RecruitingNCT07414043

Characterization and Phenotyping of Patients Who Are Offered Drug Therapy for Obesity

391/2025/OssF/AOUBo

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

500 participants

Start Date

Oct 22, 2025

Study Type

OBSERVATIONAL

Conditions

Obesity, Overweight

Summary

The study is multicenter and observational, consisting of a cross-sectional phase (V0) in which data will be collected from patients who are offered drug therapy, and a prospective longitudinal phase in which only patients who agree to start drug therapy for obesity will be involved

Eligibility

Min Age: 12 Years

Inclusion Criteria1

Therapeutic indication for taking one of the following drugs for the treatment of obesity: Orlistat, Naltrexone/Bupropion (Mysimba®), Liraglutide (Saxenda®), Semaglutide (Wegovy®), Tirzepatide (Mounjaro®)

Exclusion Criteria4

\- Secondary forms of obesity:
Hypothalamic obesity (both monogenic and acquired forms);
Syndromic obesity (e.g., Prader-Willi, Alstrom, Bardet Biedl, etc.);
Endocrinopathies associated with obesity (Cushing's syndrome, uncompensated hypothyroidism)

Interested in this trial?

Get notified about updates and connect with the research team.